China National Medicines Corp Ltd (600511) - Total Liabilities
Based on the latest financial reports, China National Medicines Corp Ltd (600511) has total liabilities worth CN¥15.19 Billion CNY (≈ $2.22 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore China National Medicines Corp Ltd (600511) net asset momentum to track the company's year-over-year net asset growth rate.
China National Medicines Corp Ltd - Total Liabilities Trend (1999–2024)
This chart illustrates how China National Medicines Corp Ltd's total liabilities have evolved over time, based on quarterly financial data. See 600511 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
China National Medicines Corp Ltd Competitors by Total Liabilities
The table below lists competitors of China National Medicines Corp Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nicolet Bankshares Inc.
NYSE:NIC
|
USA | $13.32 Billion |
|
COFCO Capital Holdings Co Ltd
SHE:002423
|
China | CN¥140.48 Billion |
|
Shufersal
TA:SAE
|
Israel | ILA11.23 Billion |
|
LG Display
KO:034220
|
Korea | ₩20.80 Trillion |
|
Jiangsu Changshu Rural Commercial Bank Co Ltd
SHG:601128
|
China | CN¥369.64 Billion |
|
Hayward Holdings Inc
NYSE:HAYW
|
USA | $1.52 Billion |
|
Rev Group Inc
NYSE:REVG
|
USA | $783.70 Million |
Liability Composition Analysis (1999–2024)
This chart breaks down China National Medicines Corp Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see China National Medicines Corp Ltd market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how China National Medicines Corp Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for China National Medicines Corp Ltd (1999–2024)
The table below shows the annual total liabilities of China National Medicines Corp Ltd from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥15.95 Billion ≈ $2.33 Billion |
+6.93% |
| 2023-12-31 | CN¥14.92 Billion ≈ $2.18 Billion |
+8.51% |
| 2022-12-31 | CN¥13.75 Billion ≈ $2.01 Billion |
+4.80% |
| 2021-12-31 | CN¥13.12 Billion ≈ $1.92 Billion |
+11.08% |
| 2020-12-31 | CN¥11.81 Billion ≈ $1.73 Billion |
-1.86% |
| 2019-12-31 | CN¥12.03 Billion ≈ $1.76 Billion |
+10.41% |
| 2018-12-31 | CN¥10.90 Billion ≈ $1.60 Billion |
+1.78% |
| 2017-12-31 | CN¥10.71 Billion ≈ $1.57 Billion |
+216.41% |
| 2016-12-31 | CN¥3.38 Billion ≈ $495.28 Million |
+11.27% |
| 2015-12-31 | CN¥3.04 Billion ≈ $445.10 Million |
+2.86% |
| 2014-12-31 | CN¥2.96 Billion ≈ $432.71 Million |
+2.55% |
| 2013-12-31 | CN¥2.88 Billion ≈ $421.94 Million |
+7.20% |
| 2012-12-31 | CN¥2.69 Billion ≈ $393.60 Million |
+33.24% |
| 2011-12-31 | CN¥2.02 Billion ≈ $295.41 Million |
-1.50% |
| 2010-12-31 | CN¥2.05 Billion ≈ $299.92 Million |
+21.01% |
| 2009-12-31 | CN¥1.69 Billion ≈ $247.84 Million |
+50.07% |
| 2008-12-31 | CN¥1.13 Billion ≈ $165.15 Million |
-8.24% |
| 2007-12-31 | CN¥1.23 Billion ≈ $179.99 Million |
+59.53% |
| 2006-12-31 | CN¥771.05 Million ≈ $112.83 Million |
+1.55% |
| 2005-12-31 | CN¥759.27 Million ≈ $111.11 Million |
+7.78% |
| 2004-12-31 | CN¥704.48 Million ≈ $103.09 Million |
+13.66% |
| 2003-12-31 | CN¥619.80 Million ≈ $90.70 Million |
+51.63% |
| 2002-12-31 | CN¥408.75 Million ≈ $59.81 Million |
+35.80% |
| 2001-12-31 | CN¥300.99 Million ≈ $44.04 Million |
+16.51% |
| 2000-12-31 | CN¥258.33 Million ≈ $37.80 Million |
-42.44% |
| 1999-12-31 | CN¥448.80 Million ≈ $65.67 Million |
-- |
About China National Medicines Corp Ltd
China National Medicines Corporation Ltd., together with its subsidiaries, engages in pharmaceutical equipment circulation in China. The company also manufactures and sells new drugs; sells Chinese patent medicines drug sales and western medicines, and medical equipment; and offers dental academic services, warehousing, logistics and import and export agency services. It also serves hospitals, re… Read more